How immune cells interact in lymph nodes to fight cancer
Official title: Integrin-mediated regulation of type-1 dendritic cell positioning and function in lymph nodes
Funded at University of Washington · NIH-11114593 · Data updated 2026-11-12
This study is looking at how certain immune cells in your lymph nodes work together to help your body fight cancer, and it aims to find ways to make cancer treatments more effective for patients like you.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | April 23, 2025 |
| Project end | March 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $264,750 |
| NIH project number | 1R21AI190507-01 |
| Project ID | NIH-11114593 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with cancer who are seeking innovative treatments that harness the immune system.
✕Less likely to help
Patients with non-cancerous conditions or those who are not eligible for immunotherapy may not benefit from this research.
What this research studies
This research investigates how specific immune cells, known as dendritic cells, are positioned and function within lymph nodes to enhance the body's ability to fight cancer. It focuses on understanding the role of integrins, which are proteins that help these cells attach to blood vessels and communicate with other immune cells. By studying the interactions between different types of dendritic cells, the research aims to improve the effectiveness of anti-tumor immune responses. This could lead to better strategies for cancer immunotherapy, potentially making treatments more effective for patients.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer immunotherapies that enhance the body's immune response against tumors.
How similar studies have gone: Previous research has shown promising results in enhancing anti-tumor immunity through similar mechanisms, indicating potential for success in this approach.
Where this research is happening
-
University of Washington
Seattle, United States Active
Researchers
- Principal investigator: Gerner, Michael — University of Washington
- Study coordinator: Gerner, Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.